BioSpace News Archive

Industry advocates argue price negotiation via the IRA may jeopardize the prices relied upon by biosimilar manufacturers to recoup their investments.

J&J, Merck and Pfizer are the subjects of a House Judiciary Committee investigation for their alleged participation in a government-sanctioned censorship campaign during the COVID-19 pandemic.

BioSpace rounded up companies with products for Alzheimer’s, ALS, Parkinson’s and Huntington’s in the final stages of clinical testing.

Johnson & Johnson and Astellas are the latest companies to file suits against the Biden administration, challenging the constitutionality of the Inflation Reduction Act’s Drug Price Negotiation Program.

With its primary patent expiring in India this week, MSF has urged Johnson & Johnson to drop all secondary protections and withdraw pending applications for the drug-resistant tuberculosis drug.

Late-stage study suggests Merck’s Keytruda is a promising treatment candidate in newly diagnosed patients with locally advanced cervical cancer, inducing better progression-free survival.

Nicox SA provided financial and business highlights for the second quarter 2023 for Nicox SA and its subsidiaries.

RELIEF THERAPEUTICS Holding SA announced an extension of its exclusive, long-term agreement with Pentec Health, Inc., broadening the distribution of PKU GOLIKE® in the U.S. Pentec Health is a leading provider of healthcare services for complex care challenges, including clinical nutrition and specialty care, and the exclusive distributor of PKU GOLIKE® in the U.S.

Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, announces new positive clinical data from the Company’s ongoing Phase I/II BEXMAB study.

Biophytis SA announced that it has entered into definitive agreements for the purchase and sale of 1,333,334 units, each consisting of one American Depositary Share or one prefunded warrant giving right to one ADS and one warrant to purchase one ADS, at a purchase price of $2.85 per unit comprising an ADS and $2.84 per unit comprising a prefunded warrant.